Hims & Hers Chief Executive Andrew Dudum pushed back against a Federal Trade Commission lawsuit filed in July, arguing the company’s rapid expansion in digital healthcare justifies its pricing and data-sharing practices.
Speaking on CNBC’s Squawk Box, Dudum framed Hims & Hers as an ‘active disruptor’ reshaping access to prescription medications, including weight-loss drugs. The FTC, along with Los Angeles County and Utah, alleges the company shared sensitive user health data with advertisers such as Meta and Snap, charged customers for prescriptions before consulting providers, and made cancellations difficult. Hims & Hers disputes these claims, asserting it has worked with regulators to address concerns.
Dudum also addressed a separate legal dispute with Novo Nordisk, which had sued the company in March 2025 over patent infringement related to compounded versions of GLP-1 weight-loss medications. The case was resolved in March when Novo Nordisk dropped its lawsuit and Hims & Hers agreed to sell Novo’s branded drugs on its platform. Dudum defended the company’s decision to offer lower-cost compounded versions during shortages, stating it exposed affordability gaps in the market and pressured drugmakers to adjust pricing.
The company’s current monthly cash-pay prices range from $150 to $200, with Dudum projecting future costs between $40 and $50 per month depending on medication form. Hims & Hers is also investing in proprietary AI technology, shifting away from third-party AI agents to build its own systems, a move Dudum described as critical to maintaining its competitive edge.
Dudum emphasized the value of Hims & Hers’ proprietary health data ecosystem, stating that closed-loop datasets within healthcare systems are the company’s core asset. He argued that traditional healthcare models lack the same depth of consumer insights, reinforcing the company’s long-term strategy despite regulatory scrutiny.
